A novel alternative to ocular drug delivery system: Hydrogel

International Journal of Pharmaceutical Research

Volumn 2, Issue 1, 2010, Pages 2-13

  Shastri, Divyesh H ^a   Patel, Lakshamanbhai D ^b  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b C U SHAH UNIVERSITY   (India)

Author keywords

Environment sensitive; Hydrogel; Insitu; Ocular drug delivery; Preformed

Indexed keywords

CARBOPOL 940; CARTEOLOL; CELLACEFATE; PILOCARPINE; POLOXAMER; POLYCARBOPHIL; POLYMER; TIMOLOL MALEATE; TIMOPTOL XE; UNCLASSIFIED DRUG; XANTHAN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUTION; ENZYME SUBSTRATE; HEAT SENSITIVITY; HUMAN; HYDROGEL; INTRAOCULAR PRESSURE; IONIC STRENGTH; NONHUMAN; PH; PHASE TRANSITION; PHYSICAL CHEMISTRY; SENSITIVITY ANALYSIS; STIMULUS RESPONSE;

EID: 79952089928     PISSN: None     EISSN: 09752366     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Joshi A, Ding S, Himmelstein KJ. Reversible gelation composition and method of use. US Patent No. 5,252,318; October 12 (1993).
2. Kumar S, Haglund BO and Himmelstein KJ. In situ forming gels for ophthalmic drug delivery. J Ocul Pharmacol. 1994; 10:47-56.
3. Le Bourlais C, Aear L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems: recent advances. Prog Retinal Eye Res. 1998; 17 (1):33-58.
4. Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, J. Pharm. Sci. 1976, 65, 1295-1301.
5. 14C] acrylate nanoparticles in albino rabbits, Int J Pharm 1985; 23:175-183.
6. Lee VHL and Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine in albinos rabbit; J. Pharm. Sci., 1979; 68:673-684.
7. Keister JC, Cooper ER, Missel PJ, Lang JC and Hager DF. Limits on optimizing ocular drug delivery. J. Pharm. Sci. 1991; 80:50-53.
8. Ching HS, Park H, Kelly P, and Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery. II. Synthesis and evaluation of some swelling, water insoluble bioadhesive polymers. J. Pharm. Sci., 74:399 (1985).
9. Lee VHL, Topical Ocular Drug Delivery: Recent Advances and Future Perspectives. Pharm. Int. 1985; 6:135-138.
10. Robinson JR, Ocular evaluation of polyvinyl alcohol vehicle in rabbits; J. Pharm. Sci. 1975; 64:1312-1316.
11. Krishnamorthy R. Mucoadhesive polymers in ocular drug delivery, In: Mitra AK, ed. Ophthalmic drug delivery systems. New York: Marcel Dekker, 1993:199-221.
12. Plazonnet B, In Ophthalmic Drug Delivery; Biopharmaceutical, Technological and Clinical Aspects, Liviana press, 1987: 117-139.
13. Van M., In Biopharmaceutics of ocular drug delivery, Ed. P. Edman, CRC press, Boca Raton, Fla., 1993: 27-42.
14. Soppinath KS, Aminabhavi, TM, Dave AM, Kumbar SG, Rudzinski WE, Stimulusresponsive "smart" hydrogels as novel drug delivery systems. Drug Dev. Ind. Pharm. 2002; 28: 957-74.
15. Miller S, Donovan M. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int. J. Pharm., 1982; 12:147-152.
16. Wichterle O, Lim D, Hydrophilic gels for biological use. Nature 1960; 185:117-118.
17. Qiu Y, Park K, Environment-sensitive hydrogels for drug delivery. Adv. Drug. Deliv. Rev. 2001; 53:321-39.
18. Kim SW, Temperature Sensitive Polymers for Delivery of Macromolecular Drugs, in Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems, Ogata N, Kim SW, Feijen J, et al. (eds), Tokyo, Springer, 1996: 126-133.
19. Kaur IP, Kanwar M, Ocular preparation: the formulation approach. Drug Devel Indust Pharm. 2002; 28(5):373.
20. Anseth KS, Metters AT, Bryant SJ, Martens PJ, Elisseeff JH, Bowman CN, In situ forming degradable networks and their application in tissue engineering and drug delivery. J Control Release, 2002; 78:199-209.
21. Matsuda T, Device-directed therapeutic drug delivery systems. J Control Release 2002; 78:125-31.
22. Obara K, Ishihara M, Ishizuka T, Fujita M, Ozeki Y, Maehara T. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healingimpaired db/db mice. Biomaterials, 2003; 24:3437-44.
23. Ramanathan S, Block LH, The use of chitosan gels as matrices for electrically modulated drug delivery. J Control Release, 2001; 70:109-23.
24. Jensen M, Hansen PB, Murdan S, Frokjaer S, Florence AT, Loading into electro-stimulated release of peptides and proteins from chondroitin 4-sulphate hydrogels. Eur J Pharm Sci. 2002; 15:139-48.
25. Podual K, Doyle FJ, Peppas NA, Dynamic behavior of glucose oxidase-containing microparticles of poly (ethylene)-grafted cationic hydrogels in an environment of changing pH. Biomaterials, 2000; 21:1439-50.
26. Obaidat A, Park K, Characterization of protein release through glucose-sensitive hydrogel membranes. Biomaterials; 1997; 18:801-6.
27. Hisamitsu I, Kataoka K, Okana T, Sakurai Y, Glucose-responsive gel from phenyl borate polymer and poly (vinyl alcohol): prompt response at physiological pH through the interaction of borate with amino group in the gel. Pharm Res. 1997; 14:289-93.
28. Wei G, Xu H, Ding PT, Li SM, Zheng JMJ, Thermosetting gels with modulated gelation temperature for ophthalmic use. The reheological and gamma scintigraphic studies. J Conttolled Rel. 2002; 83:64-65.
29. Peppas NA, Bures P, Leo Bandung W, Ichikawa H, Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000; 50:27-46.
30. Bromberg LE, Ron ES, Temperature responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv. Drug Deliv. Rev. 1998; 31:197-221.
31. Kono K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 2001; 53:307-19.
32. Alexandridis P, Hatton JA. Poly (ethylene oxide) Poly (propylene oxide)-poly (ethylene oxide) block co-polymer surfactants in aqueous solutions and at interface thermodynamic, structure, dynamic, and modeling. Colloids surface. 1995; 96:1-46.
33. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release. 2002; 83:65-74.
34. Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo convocal microscopy to the objective evaluation of ocular irritation induced by surfactant. Int J Pharmaceut Sci. 2002; 207:89-98.
35. Chen-Chow PC, Frank SG. In vitro release of Lidocaine from Pluronic F 127. Int J Pharmaceut Sci. 1981; 8: 89-99.
36. Miller SC, Donovan MD. Effect of Poloxamer 407 gel on the miotic activities of pilocarpine nitrate in rabbit. Int J Pharmaceut Sci. 1982; 12:147-152.
37. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamers as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998; 6:105-12.
38. Ling HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000; 69:379-88.
39. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 2002; 241:47-55.
40. Miyazaki S, Suzuki S, Kawasaki A, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001; 229:29-36.
41. Bugalassi S, Chetoni P, Panichi L, Boldrini E, Saettone MF. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther. 2000; 16:497-509.
42. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Controlled Rel. 2000; 69:379.
43. Sintzel MB, Bernatchez SF, Tabatabay C, Gurny R. Biomaterial in ophthalmic drug delivery. Eur J Pharm Biopharm.1996; 42:358-374.
44. Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetic and tolerance ophthalmic hydrogel. Adv Drug Del Rev. 1995; 16:51-69.
45. Ding S. Recent advances in ophthalmic drug delivery. Pharm Sci Technol Today. 1998; 1:328-335.
46. rd Eur. Congr. Biopharm Pharmacokinetics; 1987; 1:454-455.
47. Barendsen H, Oosterhuis JA and Van Haeringen NJ, Concentration of fluorescein in tear fluid after instillation as eye-drops, Ophthal. Res. 1979; 11:73-82.
48. Boye T, Gurny R, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery, J. Control. Release. 1985; 2:353-361.
49. Gurny R. Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. Pharma Acta Helv. 1981; 56(4-5):130-132.
50. Le Bourlais CA, Treupel-Acar L., Rhodes Ct, Sado PA, Leverge R. New ophthalmic drug delivery system. Drug Dev Ind Pharm. 1995; 21:19-59.
51. Hui HW, Robinson JR. Ocular drug delivery of progesterone using of bioadhesion polymer. Int J Pharmaceut Sci. 1985; 26:203-213.
52. Davis NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery: part 1, viscous solution. Pharm Res. 1991; 8(8):1039-1043.
53. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release. 2001; 73:205-11.
54. Kumar S, Haglund BO, Himmelstein KJ. In situ-forming gels for ophthalmic drug delivery. J Ocul Pharmacol 1994; 10:47-56.
55. Robinson JR, Miynek GM, Bioadhesive and phase change polymers for ocular drug delivery. Adv Drug Del Rev. 1995; 16:147-152.
56. Kaur IP, Smith R. Penetration enhancer and ocular Bioadhesive: two new avenues for ophthalmic drug delivery. Drug Dev Indust Pharm. 2002; 28(4):353-369.
57. Aikawa K, Mitsutake A, Uda H, Tanaka S, Shimamura H, Aramaki Y. Drug release from pH-response polyvinylacetaldiethylaminoacetate hydrogel, and application to nasal delivery. Int J Pharm. 1998; 168:181-8.
58. Bhaskaran S, Lakshmi PK, Harish CG. Topical ocular drug delivery: a review. Ind J Pharm Sci. 2005; 64(4):404-408.
59. ®) in physiological conditions. Eur J Pharm Sci.1999; 9:99-105.
60. Carlfors J, Edsman K, Petersson RJ, rnving K. Rheological evaluation of Gelrite ® in situ gels for ophthalmic use. Eur J Pharm Sci. 1998; 6:113-119.
61. Hartmann V, Keipert S, In vitro and in vivo characterization of polymers for ocular use. Pharmazie. 2000; 55:440-443.
62. Rozier A, Mazuel C, Grove J and Plazonnet B. Gelrite: a novel ion activated in situ gelling effect bioavailability of timolol. Int J Pharm. 1989; 57:163-168.
63. Sanzgiri YD, Maschi S, Crescenzi V, Callengaro L, Topp EM, Stella VJ. Gellan based system for ophthalmic sustained delivery of methyl prednisolone. J Controlled Rel. 1993; 26: 195-201.
64. Maurice DM, Srinivas SP. Use of flurometry in assessing the efficacy of a cation sensitive gel as an ophthalmic vehicle: comparision with scintigraphy. J Pharm Sci. 1992; 81:615-619.
65. Cohen S, Lobel E, A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye; J. Control. Rel. 1997; 44:201-208.
66. Scchoy O, Tissi GS, Bastian C, Maurin F, Driot JY, Trnqu C. A new long acting ophthalmic formulation of Carteolol containing alginic acid. Int J Pharm. 2000; 207:109-116.
67. Schenkar HI, Silver LH. Long term intraocular pressure lowering efficiency and safety of timolol maleate gel forming solution 0.5% compared with Timoptic XE 0.5% in a 12 month study. Am J Ophthalmol. 2000; 13:145-150.
68. Shedden A, Laurence J, Tipping R. Efficacy and tolerability of timolol maleate gel forming solution in adults with open angle glaucoma or ocular hypertension: a six month double masked multicenter study. Clinical Ther. 2001; 23:440-450.
69. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma. 1998; 7: 402-407.
70. Rosenlund EF. The intraocular pressure lowering effects of timolol in gel forming solution. Acta Ophthalmol Sand. 1996; 74:160-162.
71. Ricci EJ, Bentley MV, Farah M, Bretas RES, Marchetti JM. Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci. 2002; 17:161-167.
72. Paavola AY, liruusi J, Rosenberg P. Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels. J Control Release. 1998; 52: 169-178.
73. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm. 1999; 184:189-198.
74. Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Control Release. 1997; 49:21-26.
75. DesNoyer JR, McHugh AJ. The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release. 2003; 86:15-24.
76. Kim YJ, Choi S, Kohl JJ, Lee M, Kim SW. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm. Res. 2001; 18:548-550.
77. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drugdelivery systems. Nature. 1997; 388:860-862.
78. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000; 21:2155-2161.
79. Suisha F, Kawasaki A, Miyazaki S, Shirakawa M, Yamatoya K, Sasaki M. Xyloglucan gels as sustained release vehicles for the intraperitoneal administration of mitomycin C. Int J Pharm. 1998; 172:27-32.
80. Matschke C, Isele U, Van Hoogevest P, Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release. 2002; 85:1-15.
81. Carelli V, Coltelli S, Di Colo G, Nannipieri E, Serafini MF. Silicone microspheres for pHcontrolled gastrointestinal drug delivery. Int J Pharm. 1999; 179:73-83.
82. Kubo W, Miyazaki S, Attwood D. Oral sustained delivery of paracetamol from in situgelling gellan and sodium alginate formulations. Int J Pharm. 2003; 258:55-64.
83. Choi HG, Oh YK, Kim CK. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: en-hanced bioavailibility. Int J Pharm. 1998; 165:23-32.
84. Charrueau C, Tuleu C, Astre V, Grossiord JL, Chaumeil JC. Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids. Drug Dev Ind Pharm. 2001; 27:351-357.
85. Miyazaki S, Suisha F, Kawasaki A, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release. 1998; 56:75-83.
86. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci & Technol Today. 2000; 3:359-364.
87. Chang JY, Oh YK, Kong HS, Kim EU, Jang DD, Nam KT. Prolonged antifungal effects of clotrimazole-containing Mucoadhesive thermosensitive gels on vaginitis. J Control Release. 2002; 82:39-50.
88. Miyazaki S, Tobiyama T, Takada M, Attwood D. Percutaneous absorption of indomethacin from pluronic F127 gels in rats. J Pharm Pharmacol. 1995; 47:455-457.
89. Pillai O, Panchagnula R. Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release. 2003; 89:127-140.